- Services & Solutions
- Clients & Partners
SRI International Names Mariann Byerwalter Chairman of the Board and Welcomes Wendell Wierenga to Board of Directors
MENLO PARK, Calif.—January 15, 2014 – SRI International, a prestigious research and innovation center, has named Mariann Byerwalter as Chairman of SRI International’s Board of Directors, effective January 1, 2014. Admiral Vern Clark, who had been chairman since 2010, will remain on the Board.
Byerwalter was most recently Chairman of the Board of Directors of Stanford Hospital and Clinics and is a former Trustee of Stanford University. Prior to that, she served as Chief Financial Officer of Stanford University, and joined SRI’s Board in 1998. Her broad business, finance and administrative background includes government cost and rate studies, business development, and information technology systems and services. In addition, Byerwalter serves on the Boards of Burlington Capital Group, Lucile Packard Children’s Hospital, Pacific Life Insurance, Redwood Trust, Inc., SchwabFunds, and WageWorks.
Byerwalter has a B.A. degree from Stanford University and an MBA from Harvard Business School. She received the 1998 Financial Woman of the Year Award from the Financial Women’s Association of San Francisco, is a Distinguished Honoree for the Harvard Business School Association of Northern California’s “50 Years of Women at HBS” and has been selected as an Outstanding Director for 2014 by the San Francisco Business Times and Silicon Valley Business Journal.
Newly elected to SRI’s Board of Directors is Wendell Wierenga, Ph.D., executive vice president of research and development at Santarus, Inc. Wierenga brings extensive experience in research, drug discovery and drug development including clinical research, regulatory affairs, manufacturing, safety, and medical affairs.
Wierenga is on the Scientific Advisory Boards of Concert Pharmaceuticals, Ferring Pharmaceuticals, and aTyr Pharma, Inc. He also serves on the Boards of Directors of Cytokinetics, Inc., Onyx Pharmaceuticals, Inc., and XenoPort, Inc.
Previously, Wierenga held the position of executive vice president of R&D at Ambit and at Neurocrine Biosciences. Prior to Neurocrine, he was CEO of Syrrx, Inc., and senior vice president of worldwide pharmaceutical sciences, technologies, and development at Parke-Davis/Warner Lambert (now Pfizer). Wierenga also spent 16 years at Upjohn Pharmaceuticals, where his last position was executive director of discovery research. He led and participated in more than 70 Investigational New Drug (IND) disclosures, more than 15 New Drug Applications (NDAs), and marketed 16 products, including Lipitor®, Neurontin®, Lyrica®, and Uceris®.
Wierenga earned his Ph.D. in chemistry from Stanford University.